Hanmi Pharmaceutical, Co., Ltd
45, Bandi-dong, Songpa-gu
Seoul
138-724
Tel: +82-31-371-5027
Fax: +82-31-371-5006
Website: http://www.hanmipharm.com/eng/
61 articles about Hanmi Pharmaceutical, Co., Ltd
-
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
1/31/2024
Aptose Biosciences Inc. announced the closing of the previously announced public offering of 5,649,122 common shares of the Company and warrants at a combined offering price of US $1.71 per share.
-
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
9/6/2023
Aptose Biosciences Inc. announced closing of a $3 million investment in common shares of the Company as the first tranche of a private equity investment for up to a maximum of $7 million or 19.99 percent ownership interest by Hanmi Pharmaceutical, Inc., Seoul, South Korea.
-
Hanmi Fine Chemical Launches 'high-tech CDMO' Business
5/23/2022
Hanmi Fine Chemical a subsidiary of Hanmi Pharmaceutical Group specializing in APIs development and manufacturing, is now accelerating a new business, expanding its specialties from ongoing APIs to 'high-tech CDMO' services.
-
Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharmaceutical
1/4/2022
Spectrum Pharmaceuticals today announced a $20 million equity investment by Hanmi Pharmaceutical along with revisions to the licensing agreements for ROLONTIS ® (eflapegrastim) and poziotinib.
-
Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239
11/4/2021
Aptose Biosciences Inc., announced that it has entered into an exclusive license agreement with Hanmi Pharmaceutical, a South Korean pharmaceutical company, to develop and commercialize HM43239, an oral, highly potent, clinical-stage myeloid kinome inhibitor, designed to target a distinct constellation of kinases operative in myeloid malignancies, including SYK, FLT3, and others.
-
Hanmi Pharmaceutical finds new innovative potential for "Efpeglenatide"
6/29/2021
Hanmi Pharmaceutical recently announced that its new, long-acting diabetes biologic drug, efpeglenatide, was shown to significantly reduce incidences of major adverse cardiovascular events and kidney disease in the results of its global, large-scale clinical trial with more than 4,000 patients.
-
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)
8/4/2020
Merck and Hanmi Pharmaceutical announced that the companies have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide, Hanmi’s investigational once-weekly glucagon-like peptide-1 /glucagon receptor dual agonist, for the treatment of nonalcoholic steatohepatitis.
-
Merck entered into an exclusive licensing deal with Hanmi Pharmaceutical for the development, manufacture and commercialization of efinopegdutide for nonalcoholic steatohepatitis (NASH).
-
Hanmi Pharmaceutical participated in the 38th J.P. Morgan Healthcare Conference, announces that it is "ready to lead global pharmaceutical market with innovative R&D pipeline"
1/15/2020
Hanmi Pharmaceutical has taken a bold step into 2020, to embrace new challenges to innovative research and development pipelines
-
RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia
12/3/2019
FLX475 is an oral, small molecule CCR4 antagonist in development for the treatment of multiple cancers.
-
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-PD-1/HER2 Bispecific Antibody in China
11/26/2019
CIBI315A101 is a phase I clinical trial conducted in China to evaluate the safety, tolerability, initial efficacy and recommended Phase II dose of IBI315 in the treatment of patients with HER2-expressing advanced solid malignancies
-
Like many other big pharma companies, Eli Lilly & Co. reported a good 2018 with a less optimistic view of 2019. Fourth-quarter 2018 revenue grew by 5 percent, driven by newer drugs. Operating expenses also went up by a percentage point. Full-year 2018 revenue grew by 7 percent to $24.556 billion.
-
Eli Lilly and its Korean collaborative partner Hanmi stopped a Phase II trial on an experimental rheumatoid arthritis treatment following less-than-stellar interim results.
-
Hanmi Pharma Charged for Failure to Report Patient Death in Olmutinib Study
4/18/2017
-
Hanmi Pharma/Beijing Hanmi And Innovent Enter Into A Global Strategic Partnership To Co-Develop A Novel Immuno-Oncology Bispecific Antibody
3/30/2017
-
Johnson & Johnson Hits Roadblock as Recruitment in Diabetes Drug Study From Hanmi Pharma is Halted
12/7/2016
-
Hanmi Pharma’s Q3 Operating Profit Plunges 62%
10/27/2016
-
Cell Phones and Documents are Seized From Some Hanmi Pharma Employees on Suspicion of Insider Information Leak
10/11/2016
-
Deaths Lead Boehringer Ingelheim to Cancel $730 Million Cancer Deal With Hanmi Pharma, Hanmi Stock Tanks
10/6/2016
-
Next in a String of Deals, Korea’s Hanmi Pharma Inks $910M Deal with Genentech
9/30/2016